Dan McCarthy - Evolent Health CEO Pres
| 9EH Stock | EUR 10.70 0.40 3.88% |
Insider
Dan McCarthy is CEO Pres of Evolent Health
| Phone | 571 389 6000 |
| Web | https://www.evolenthealth.com |
Dan McCarthy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dan McCarthy against Evolent Health stock is an integral part of due diligence when investing in Evolent Health. Dan McCarthy insider activity provides valuable insight into whether Evolent Health is net buyers or sellers over its current business cycle. Note, Evolent Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Evolent Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dan McCarthy over three months ago Acquisition by Dan McCarthy of 3000 shares of Evolent Health at 10.65 subject to Rule 16b-3 | ||
Dan McCarthy over six months ago Disposition of 5638 shares by Dan McCarthy of Evolent Health at 34.41 subject to Rule 16b-3 |
Evolent Health Management Efficiency
Evolent Health's management efficiency ratios could be used to measure how well Evolent Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA LLM | Compugroup Medical SE | 51 | |
| Tyson Murdock | Healthequity | 52 | |
| Claudia Thom | Compugroup Medical SE | 52 | |
| Angela Teufer | Compugroup Medical SE | 50 | |
| Thomas Schwenger | Veeva Systems | 55 | |
| Bradford Crutchfield | 10X GENOMICS DL | 56 | |
| Sandra Fenwick | Teladoc | 68 | |
| Bryan Roberts | 10X GENOMICS DL | 52 | |
| Brent Bowman | Veeva Systems | 56 | |
| Shehnaaz Suliman | 10X GENOMICS DL | 47 | |
| Eckart Pech | Compugroup Medical SE | 54 | |
| Brad Crutchfield | 10X GENOMICS DL | N/A | |
| Andrew Turitz | Teladoc | 50 | |
| George Brooks | Teladoc | N/A | |
| Glen Tullman | Teladoc | N/A | |
| Karen Daniel | Teladoc | 61 | |
| CPA CFA | Teladoc | N/A | |
| Jacques Mourrain | Veeva Systems | N/A | |
| Christopher Bischoff | Teladoc | 46 | |
| Mike Waters | Teladoc | N/A | |
| Michelle Bucaria | Teladoc | 48 | |
Management Performance
| Return On Equity | -0.0241 | |||
| Return On Asset | 0.002 |
Evolent Health Leadership Team
Elected by the shareholders, the Evolent Health's board of directors comprises two types of representatives: Evolent Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolent. The board's role is to monitor Evolent Health's management team and ensure that shareholders' interests are well served. Evolent Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolent Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, Gen Officer | ||
| Aammaad Shams, Chief Controller | ||
| Jessica Somers, Sr Devel | ||
| Seth Frank, VP Relations | ||
| MAAA FSA, Chief Officer | ||
| John Johnson, Chief Officer | ||
| Seth Blackley, CEO CoFounder | ||
| Frank Williams, CoFounder Chairman | ||
| Kali Beyah, Chief Officer | ||
| Dan McCarthy, CEO Pres |
Evolent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolent Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0241 | |||
| Return On Asset | 0.002 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0 % | |||
| Current Valuation | 3.01 B | |||
| Shares Outstanding | 111.05 M | |||
| Shares Owned By Insiders | 14.57 % | |||
| Shares Owned By Institutions | 92.75 % | |||
| Price To Book | 3.31 X | |||
| Price To Sales | 2.16 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Evolent Stock
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.